Biocon Limited has formally declared that its promoters and promoter group entities maintained no encumbrance on shares throughout the financial year 2025-26. The biotechnology company submitted this declaration on April 02, 2026, in compliance with regulatory requirements under SEBI's takeover regulations.

Regulatory Compliance Declaration

The declaration was made pursuant to Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Syngene International received formal notification along with both major stock exchanges regarding this compliance matter.

Share Encumbrance Status

The company confirmed that none of the entities belonging to the promoter and promoter group category, along with persons acting in concert, created any encumbrance on shares held directly or indirectly in the company. This declaration covers the entire duration of the financial year 2025-26 and the position as of March 31, 2026.

Corporate Communication

Company Secretary and Compliance Officer Rajesh Umakant Shanoy, membership number ACS 16328, digitally signed the declaration from Bengaluru. The formal communication was addressed to multiple parties including the Audit Committee Chairperson, BSE Limited's Department of Corporate Services, and the National Stock Exchange of India Limited's Corporate Communication Department.

This declaration represents standard regulatory compliance for listed companies, ensuring transparency in promoter shareholding patterns and maintaining investor confidence through proper disclosure of any potential encumbrances on promoter holdings.

Syngene International Limited has formally notified the stock exchanges about an upcoming board meeting scheduled to review its financial performance and consider dividend distribution for shareholders.

Board Meeting Details

The company has announced that its Board of Directors will convene on Wednesday, April 29, 2026, to undertake several key agenda items. The meeting has been scheduled in compliance with Regulation 29(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Key Agenda Items

The board will consider and approve the audited standalone and consolidated financial results for the quarter and year ending March 31, 2026. Additionally, the directors will deliberate on the recommendation of final dividend, if any, amongst other routine matters that typically form part of such meetings.

Trading Window Restrictions

In accordance with regulatory compliance, the company has implemented mandatory trading restrictions for insiders. The trading window for dealing in securities has been closed from April 01, 2026, and will remain shut until the close of trading hours on May 01, 2026.

This closure period extends until 48 hours after the declaration of financial results, ensuring compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, as well as the company's internal code of conduct for Prevention of Insider Trading.

Investor Engagement

Syngene International will organize a conference call for analysts and investors on Thursday, April 30, 2026, following the board meeting. The company has indicated that detailed information regarding the conference call will be made available on its official website closer to the scheduled event, allowing stakeholders to participate in the earnings discussion and seek clarifications on the financial performance.